Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma

摘要: Conclusion. This study could not attribute survival differences to the coincident acquisition of two common genetic alterations, K-ras mutation and p53 overexpression in pancreatic adenocarcinoma patients. Additionally, our data indicate converse be true: Those patients lacking both aberrant expression showed shortest when compared with cases showing either alteration or both. also negative effect on pancreas cancer patients' after treatment radiation therapy chemotherapy. Background. Mutations oncogene at codon 12 are reported most carcinoma, whereas tumor suppressor gene is considered neoplasia all types. has been attributed but such association still controversial. No studies have fully documented combined incidence alterations adenocarcinoma, their patient a large case series. The influence chemotherapy groups both, either, neither undocumented. Methods. Paraffin-embedded tissue sections from 76 were cut for DNA extraction analysis immunohistochemical staining expression. was determined by single-strand conformation polymorphism (SSCP) slot-blot allele-specific oligonucleotide (ASO) hybridization ofPCR-amplified product. scored basis percent nuclear MAb D07. Results. Sixty-four (84%) mutation, expression, mutated 55 (72%). expressed 33 (43%). Twenty-four (31%) presence related significant grade, stage, alone. A sizable subset (16% cases) lacked alteration, surprisingly, this group median those 3 (p= 0.024). Patients whose tumors K-ras-negative greatest difference (median 30.8 mo vs 7.8 no radiation, p = 0.005).